

Special Issue

Animal Herpesviruses

Message from the Guest Editors

The Herpesviridae family includes herpesviruses that infect vertebrates and invertebrates. One of the characteristics of this viral family is they establish a life-long after primary infection. Subsequently, the virus persists in neurons within the peripheral and/or the central nervous system. Periodically, herpesviruses reactivate from latency culminating in virus transmission. Stimuli that are known triggers of reactivation are: immune-suppression, stress, dramatic changes in temperature, change of feed, pregnancy, and/or overfeeding. Preventing clinical conditions of viral infection is dependent on vaccination. In addition to traditional products, certain so-called marker vaccines are available in Europe. Another essential aspect of these viruses is the potential to evoke zoonotic spread. For this Special Issue, we encourage all researchers to submit manuscripts on herpesvirus pathogenesis, immune responses, diagnostic tools, meta-analysis, or epidemiological studies. Manuscripts focused on herpesviruses vaccinology studies are also welcome.

Guest Editors

Dr. Stefano Petrini

National Reference Centre for Infectious Bovine Rhinotracheitis (IBR), Istituto Zooprofilattico Sperimentale Umbria-Marche, Perugia, Italy

Prof. Dr. Clinton Jones

Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK, USA

Deadline for manuscript submissions

closed (30 September 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/125137

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).